CRISPR Gene Editing Market Poised to Garner Maximum Revenues during Forecast 2020-2030

According to BIS Research, CRISPR technology is a tool for gene editing. It allows to alter the DNA sequences and modify gene function. Potential applications of the CRISPR technology include correction of genetic defects, treatment and prevention of the spread of diseases, and improvement in crops. The CRISPR technology is a highly programmable, rapid diagnostic tool expected to disrupt the COVID-19 diagnostic market, which is currently dominated by PCR-based testing. However, its promise also raises ethical concerns in human genome editing process, which is referred to a process of making genetic modifications to human embryos and reproductive cells.

With several companies eagerly competing to establish dominance in the global CRISPR gene editing market, there have been a large number of highly emerging and dynamic companies that have undertaken significant activities to establish their position in the market. Although these companies are currently far behind the market leaders, some of them have made significant strides to grow into major players, owing to initiatives undertaken to expand their respective product lines.

The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.

Opportunities that are likely to boost the growth of the CRISPR gene editing market includes expanding the gene and cell therapy area and increasing scope of CRISPR gene editing in agriculture. The applications for which CRISPR gene editing can be used include agricultural, biomedical (gene therapy, drug discovery, and diagnostics), industrial, and other applications [genetically modified foods (gm foods), biofuel, and animal (livestock) breeding] The end users of CRISPR gene editing include academic institutes and research centers, biotechnology companies, contract research organizations (CROs), and pharmaceutical and biopharmaceutical companies.

Key companies operating in the market include CRISPR Therapeutics, Horizon Discovery Group PLC, Cellecta, Inc., Integrated DNA Technologies, Inc., GenScript Biotech, ToolGen, Inc., System Biosciences LLC, Thermo Fisher Scientific, Inc., Origene Technologies, Inc., GeneCopoeia, Inc., New England Biolabs, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Abcam, Inc., Rockland Immunochemicals, Inc., Synthego Biosciences, Merck KGaA and Takara Bio.

Growth Drivers

• Prevalence of Genetic Disorders and Use of Genome Editing

• Government and Private Fundin

• Technology Advancement in CRISPR Gene Editing.

Market Restraints

• CRISPR Gene Editing: Off Target Effects and Delivery

• Ethical Concerns and Implications with Respect to Human Genome Editing

Market Opportunities

• Expanding Gene and Cell Therapy Area

• CRISPR Gene Editing Scope in Agriculture

Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Request a Sample - https://bisresearch.com/requestsample?id=1057&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Market Research Reports

Search This Blog